Oral vs Topical Minoxidil: What the Head-to-Head Trials Found
The short version
- It is the same drug. The foam and solution are sold over the counter in the US for men's crown thinning. The tablets are prescription-only, and their US label covers only severe high blood pressure, so taking them for hair loss is off-label.
- The only head-to-head trial in men (90 men, 24 weeks) used a 5 mg tablet, the same figure as the label's starting dose for blood pressure. It did not show the tablet was better on its main measure.
- In that trial, body-hair growth was reported by 49% of men on the tablet and 25% on the solution. Early shedding was more common with the solution (16%) than the tablet (9%).
- Both labels say the same thing about stopping: the new hair does not last.
Why this page exists
Searches for oral minoxidil, and for the 2.5 mg tablet in particular, have risen sharply this year. Most answers repeat that the pill is "more convenient and possibly more effective". We read the tablet's prescribing label, the over-the-counter labels and the published trials to see what the numbers actually say.
We sell a laser cap, not minoxidil in any form. Nothing here is advice to start, stop or switch a medicine. That decision belongs with a prescriber who knows your health.
Same molecule, two different rulebooks
| Foam or solution (topical) | Tablet (oral) | |
|---|---|---|
| How you get it in the US | Over the counter | Prescription only |
| What its US label covers | Hair loss on the top of the scalp in men (vertex only) | Only severe high blood pressure that has not responded to a diuretic plus two other drugs |
| Hair loss use | On-label for the labelled product and population | Off-label |
| Label warnings | Ask a doctor first if you have heart disease; stop if chest pain, rapid heartbeat, faintness, dizziness, sudden weight gain or swelling | A boxed warning: fluid around the heart, occasionally dangerous, and worsening angina; normally given under close supervision with a beta-blocker and a diuretic |
Sources: the minoxidil 5% foam label and the 5% solution label (both men's, over the counter), and the minoxidil tablets label, all read from FDA label data in September 2026. Foam label → · Tablet label →
Two details in the men's foam and solution labels that most summaries skip: they say the product is not intended for frontal baldness or a receding hairline, and they are labelled for use by men only. Separate products are labelled for women.
The history runs backwards from what many people assume. Minoxidil was a blood-pressure tablet first. Doctors noticed hair growth as a side effect, the first report of it being tried for male pattern hair loss came in 1980, and the topical form was approved in 1988. The recent interest in the tablet is a return to where the drug started, at much lower doses.
What "low dose" means
The tablet label's starting dose for blood pressure is 5 mg once a day, and the usual effective range is 10 to 40 mg a day. Hair-loss prescribing uses doses from a fraction of a milligram up to about 5 mg.
That overlap matters when you read the evidence. The one head-to-head trial in men tested 5 mg, the same figure as the blood-pressure starting dose. Its results cannot simply be applied to the 1 mg or 2.5 mg doses that most people searching are asking about, and the reverse is also true.
The only head-to-head trial in men
In 2024, a team in Brazil published a double-blind randomised trial in JAMA Dermatology: 90 men aged 18 to 55 with crown-predominant pattern hair loss (Norwood–Hamilton 3V to 5V). Each man took either a 5 mg minoxidil capsule plus a placebo solution, or a placebo capsule plus 1 mL of 5% minoxidil solution twice a day, for 24 weeks. Hairs were counted in two small tattooed areas on the front and crown of the scalp. Read the trial →
Here are the terminal (full-thickness) hair counts from the paper's own table, for the 68 men who finished:
| Terminal hairs per cm² | Tablet: start | Tablet: week 24 | Solution: start | Solution: week 24 | Difference between groups |
|---|---|---|---|---|---|
| Front of scalp | 91.2 | 101.5 | 105.3 | 109.7 | 3.1 (not significant) |
| Crown | 96.8 | 111.4 | 134.3 | 125.4 | 23.4 (not significant) |
The authors' conclusion was that the tablet "did not demonstrate superiority" over the solution.
Where the tablet did look better. A panel of three dermatologists, who did not know which group each man was in, judged photographs. They rated the crown as improved in 70% of men on the tablet and 46% on the solution, a statistically significant difference. The percentage change in crown terminal hairs also favoured the tablet.
Why we would not lean hard on that. Four things in the paper are worth knowing:
- The solution group's crown count went down, from 134.3 to 125.4. The authors call the solution group's results "lower-than-expected". Some of the tablet's apparent advantage on the crown comes from the comparison group doing unusually badly, not only from the tablet doing well.
- The two groups started differently. The solution group began with about 37 more terminal hairs per cm² on the crown.
- Almost one in four men did not finish: 22 of 90. Most (18) dropped out because COVID-19 restrictions stopped them attending, but they were not included in the final hair counts.
- The statistical tests were one-sided. The authors tested only whether the tablet was better, which is a lower bar than the usual two-sided test.
None of this means the tablet does not work. It means the best trial so far did not show it working better than the solution, at a dose higher than most people are asking about.
What the other comparisons found
- Women: an earlier trial by the same research group compared a 1 mg tablet with 5% solution in female pattern hair loss and found no difference in hair density between the groups. Read the record →
- Men and women, 1 mg: a 2024 trial in Iran randomised 65 people to 1 mg a day by mouth or 5% solution for six months. Both groups improved on hair diameter, and there was no significant difference between them. Read the trial →
In short: across the randomised comparisons we found, neither form has been shown to beat the other.
Side effects: the numbers side by side
The side effects people ask about most are unwanted body or facial hair, heart rate and blood pressure, and swelling. These three sources measured them very differently, so read the columns separately rather than against each other.
| Tablet label (blood-pressure patients, usually 10–40 mg) | Head-to-head trial: 5 mg tablet | Head-to-head trial: 5% solution | 1,404-patient review (low-dose tablet) | |
|---|---|---|---|---|
| Extra body or facial hair | about 80% | 49% | 25% | 15.1% |
| Headache | not quantified | 14% | 2% | 0.4% |
| Swelling / fluid retention | 7% (temporary) | 2% (lower legs) | 0% | 1.3% |
| Fast heart rate | listed | none reported | none reported | 0.9% |
| Lightheadedness | listed | none reported | none reported | 1.7% |
| Scalp eczema or itching | not applicable | 2% each | 16% and 11% | not reported |
| Stopped because of side effects | not quantified | 1 of 45 | 3 of 45 | 1.7% |
Sources: tablet label; the 2024 trial (45 men per group); and a 2021 multicentre study of 1,404 people, two-thirds of them women, treated with low-dose oral minoxidil for at least three months, which reported no life-threatening side effects. Read the 1,404-patient study →
Two cautions. The 1,404-patient study looked back at clinic records and had no comparison group, so it is likely to miss side effects that nobody wrote down. And in the head-to-head trial, blood pressure and heart rate were measured only at the start and at week 24, with no significant difference between groups.
The solution is not side-effect-free either. One in four men using it in the trial reported extra body hair, and scalp irritation was far more common than on the tablet.
Can minoxidil make your hair fall out?
It can cause a burst of shedding at the start. In the head-to-head trial, 16% of men on the solution and 9% on the tablet noticed shedding in the first two months; the difference was not statistically significant. The authors explain it as hairs in the resting phase being pushed out early as new growth begins, and describe it as temporary. The paper cites earlier reports of up to 17% with the topical form.
The more lasting kind of loss comes from stopping. The foam label says continued use is necessary, "or hair loss will begin again". The tablet label says that when the drug is stopped, new hair growth stops, and it can take 1 to 6 months for hair to return to how it looked before treatment.
How long does it take?
The over-the-counter labels say results may appear at about 2 months of twice-daily use, that some men need at least 4 months, and to stop and ask a doctor if nothing has changed by 4 months. The head-to-head trial measured only once, at 24 weeks, so it cannot tell you how soon the tablet works. Anyone who tells you a precise timeline for the tablet is going beyond the published trials.
Questions to take to a prescriber
- Is my hair loss pattern hair loss, or something else that needs a different approach?
- Given my heart health, blood pressure and other medicines, is either form of minoxidil suitable for me?
- If the tablet is an option, what dose, and how would you monitor me?
- What should I do if I notice early shedding, swelling or a racing heart?
- What happens to my hair if I stop, and what is the plan if I want to?
Where a laser cap fits, and where it doesn't
We sell a laser cap, so read this with that in mind.
A laser cap is not a drug and works in a different way. It does not lower hormones and is not a blood-vessel dilator. Luxuel is FDA 510(k) cleared (K261253) to promote hair growth in men with pattern hair loss (Norwood–Hamilton IIa–V) and women with pattern hair loss (Ludwig I–II), with skin types Fitzpatrick I–IV. Cleared is not the same as approved. What 510(k) clearance means →
Some people look at laser therapy because they would rather not take a tablet or apply a solution twice a day. That is a reasonable thing to discuss with a clinician. It is a commitment of its own: 30-minute sessions, three times a week, kept up over time. Do not stop or change a medicine to try a device without speaking to the clinician who prescribed it.
Laser cap vs finasteride vs minoxidil → · How low-level laser therapy works → · Watch: pill or foam, same drug, different rules → · See the Laser Cap 272 →
The Luxuel Laser Cap 272
272 × 650nm laser diodes · FDA 510(k) cleared (K261253) · $899
See the 272 →Not intended to diagnose, treat, cure, or prevent any disease. The clinical studies referenced evaluated a clinically studied 650nm wavelength and the low-level laser therapy category broadly. Individual results vary and depend on consistent use over time. The FDA 510(k) clearance (K261253) is held by the manufacturer.
